Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat

She said the Food and Drug Administration recently relaxed the Risk Evaluation and Mitigation Strategies, or REMS, program for Filspari. During the first year of treatment patients need to undergo liver function monitoring every three months vs. prior requirements for every month. TRENDING: Palantir, Robinhood Earnings Due After Market's Tricky October Travere Therapeutics (TVTX) stock popped Friday — soaring into a profit-taking zone — on another sales beat from its linchpin drug, Filspari. Filspari treats ...